- Home
- PTA
as 12-18-2024 11:41am EST
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 1.1B | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 159.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | Dividend Payout Frequency: | Monthly | |
| EPS: | -1.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.84 - $19.67 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest News
PTA Breaking Stock News: Dive into PTA Ticker-Specific Updates for Smart Investing
PR Newswire
6 months ago
Cohen & Steers Closed-End Funds Declare Distributions for July, August, and September 2024
CNW Group
6 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
PR Newswire
6 months ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Business Wire
6 months ago
Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store
AFP
6 months ago
New Zealand scraps plan to tax livestock burps, farts
Business Wire
6 months ago
InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA
The Wall Street Journal
6 months ago
ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility
Bloomberg
6 months ago
UK Unemployment Rises in Sign Inflationary Pressures Cool
Compare PTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.